Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net Revenue	$ 24,143,919	$ 15,586,976
Cost of goods sold	2,311,221	1,616,625
Gross profit	21,832,698	13,970,351
Operating expenses
Selling, general and administrative expenses	28,053,176	18,673,404
Research and development	558,704	40,190
Depreciation and amortization	596,975	291,370
Total operating expenses	29,208,855	19,004,964
Operating loss	(7,376,157)	(5,034,613)
Other income / (expense)
Other income		14,822
Interest expense	(711)	(11,528)
Share of losses from equity method investment	(616,927)
Debt forgiveness		586,174
Total other income / (expense)	(617,638)	589,468
Net loss	(7,993,795)	(4,445,145)
Less: Net loss attributable to noncontrolling interest	(71,881)	(88,705)
Net loss attributable to Sanara MedTech common shareholders	$ (7,921,914)	$ (4,356,440)
Net loss per share of common stock, basic and diluted	$ (1.08)	$ (0.76)
Weighted average number of common shares outstanding, basic and diluted	7,341,580	5,734,537